![Jim Powderly](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jim Powderly
Keine laufenden Positionen mehr
Profil
Jim Powderly is the founder of BioCytics, Inc. which was founded in 2005.
Ehemalige bekannte Positionen von Jim Powderly
Unternehmen | Position | Ende |
---|---|---|
BioCytics, Inc.
![]() BioCytics, Inc. BiotechnologyHealth Technology BioCytics, Inc. is a privately-held biotechnology company located in an undisclosed location, focused on cancer immunotherapy. The company is based in Huntersville, NC. The company collaborates with industry and offer a range of services to support pre-clinical and early phase cellular immunotherapy development. The company's cell therapy pipeline is currently in the pre-clinical stage, but they have an IRB approved clinical trial that has enrolled over 700 healthy donors and cancer patients. The company has a high-complexity CLIA laboratory and a team of certified medical laboratory technicians, PhD scientists, biomedical engineers, laboratory assistants, and phlebotomists. The company's laboratory facilities consist of a newly built GLP laboratory, ISO-7 cleanrooms, ISO-8 anterooms and corridors, and other CGMP dedicated spaces. The company has a robust biobank consisting of diverse biospecimens from individuals consented on an IRB approved clinical trial. The company's mission is to research and develop novel ways to target cellular immunity to generate a robust antitumor response. The company was founded in 2005 by Jim Powderly and John Powderly. | Gründer | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
BioCytics, Inc.
![]() BioCytics, Inc. BiotechnologyHealth Technology BioCytics, Inc. is a privately-held biotechnology company located in an undisclosed location, focused on cancer immunotherapy. The company is based in Huntersville, NC. The company collaborates with industry and offer a range of services to support pre-clinical and early phase cellular immunotherapy development. The company's cell therapy pipeline is currently in the pre-clinical stage, but they have an IRB approved clinical trial that has enrolled over 700 healthy donors and cancer patients. The company has a high-complexity CLIA laboratory and a team of certified medical laboratory technicians, PhD scientists, biomedical engineers, laboratory assistants, and phlebotomists. The company's laboratory facilities consist of a newly built GLP laboratory, ISO-7 cleanrooms, ISO-8 anterooms and corridors, and other CGMP dedicated spaces. The company has a robust biobank consisting of diverse biospecimens from individuals consented on an IRB approved clinical trial. The company's mission is to research and develop novel ways to target cellular immunity to generate a robust antitumor response. The company was founded in 2005 by Jim Powderly and John Powderly. | Health Technology |